PHARMAZAN PHARMACEUTICALS ApS
APSActiveCVR 32478697Strandgårds Alle 81, 3600 FrederikssundWholesale of pharmaceutical and medical goods· NACE 4646Est. 2009 · 16 years old— employees
Loading company…
Overview
PHARMAZAN PHARMACEUTICALS ApS is a Danish APS based in Frederikssund, operating in the Wholesale of pharmaceutical and medical goods sector. Incorporated in 2009, the company reported a gross profit of -DKK 21.8k in its latest annual filing.
Gross profit 2025
-21.8K DKK
−46% vs 2024
EBITDA margin (of gross profit)
100.0 %
+46% vs 2024
Net profit 2025
-21.8K DKK
+46% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
<−999 %
Very weakAmong the 10% lowest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
0.1×
Very weakAmong the 10% lowest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
-372.6 %
Very weakAmong the 10% lowest rated companies in the industry
20212025
EBITDA — year on year
DKK thousandsKey figures
Annual report 2025| Gross profit | -21.8K DKK | -46% |
| EBITDA | -21.8K DKK | +46% |
| Net profit | -21.8K DKK | +46% |
| Total assets | 5.9K DKK | -13% |
| Equity | -64.1K DKK | -52% |
| Employees | — | — |
Company information
Legal name
PHARMAZAN PHARMACEUTICALS ApS
CVR number
32478697
Legal form
Anpartsselskab
NACE code
Founded
1 October 2009 · 16 years
Share capital
DKK 125,000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af de to anpartshavere i forening.
Company purpose
Selskabets formål er at drive forretning med salg af lægemidler indenfor EU/EØS samt hermed efter direktionens skøn beslægtet virksomhed.
(no translation available)
Address
Strandgårds Alle 81, 3600 Frederikssund
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), PHARMAZAN PHARMACEUTICALS ApS reported a gross profit of -DKK 21.8k. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of DKK 21.8k.
At the end of 2025, current assets covered short-term debt 0.1 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | -22 | -41 | -36 | -26 | -112 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -22 | -41 | -36 | -26 | -112 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -22 | -41 | -36 | -26 | -112 |
| Net financials | 0 | 0 | -2 | -1 | -3 |
| Profit before tax | -22 | -40 | -38 | -28 | -115 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -22 | -40 | -38 | -28 | -115 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 6 | 7 | 52 | 81 | 110 |
| Equity | -64 | -42 | -2 | 37 | 64 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 70 | 49 | 54 | 44 | 46 |
| Total debt | 70 | 49 | 54 | 44 | 46 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20212025
Equity ratio
<−999 %
Very weakAmong the 10% lowest rated companies in the industry
20212025
Return on equity
—
20212025
Net profit margin (of gross profit)
<−999 %
20212025
Asset turnover (of gross profit)
-3.73×
20212025
Debt / equity
—
20212025
Sector performance
15 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on net assets (RONA)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioVery weak
Among the 10% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery weak
Among the 10% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioWeak
Among the 30% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Cash conversion ratioWeak
Among the 40% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Debt & solvency
Solidity ratioVery weak
Among the 10% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 10% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Income to debtVery weak
Among the 20% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 20% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery weak
Among the 10% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery strong
Among the 20% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 10% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Efficiency & development
Equity to contributed capitalVery weak
Among the 20% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
One-year change in equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's equity.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JO Management | Management | 2009 |
SM Founder | Founder | 2009 |
Board of directors
Non-executive oversightNo data on file.
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 50–66.65% | 50–66.65% | 2012 | |
| Company | 50–66.65% | 50–66.65% | 2013 | |
| Individual | 50–66.65% | 50–66.65% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
HELSEFARMA ApS
PHARMAZAN PHARMACEUTICALS ApS Board network connections
Board members of PHARMAZAN PHARMACEUTICALS ApS also hold positions in 6 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steffen Møller | Founder | 4 companies |
| Jens Otto Tram | Management | 2 companies |
Frequently asked questions
What is the CVR number of PHARMAZAN PHARMACEUTICALS ApS?
PHARMAZAN PHARMACEUTICALS ApS is registered with CVR / Virk under CVR 32478697.
What is the gross profit of PHARMAZAN PHARMACEUTICALS ApS?
PHARMAZAN PHARMACEUTICALS ApS reported a gross profit of -DKK 21.8k in 2025.
Where is PHARMAZAN PHARMACEUTICALS ApS headquartered?
PHARMAZAN PHARMACEUTICALS ApS's registered address is Strandgårds Alle 81.